Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.74 |
| ▸ | LTA4H | P09960 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP7 | P09237 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP12 | P39900 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.58 |
| ▸ | CPA1 | P15085 | 1/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.58 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097324 | 1.00 | MME (0.74) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL5654469 | 1.00 | MME (0.74) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL7352159 | 1.00 | MME (0.74) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL10878801 | 0.92 | MME (0.67) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL10877122 | 0.89 | BIRC2 (0.67) | MME | |
| SCHEMBL10877116 | 0.89 | BIRC2 (0.67) | MME | |
| SCHEMBL15223611 | 0.88 | MME (0.74) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL10878767 | 0.87 | MME (0.62) | MMELTA4H | |
| SCHEMBL9068697 | 0.87 | MME (0.72) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL5869124 | 0.85 | MME (1.00) | MMELTA4HACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20030012817-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2003-01-16 | — | — | US | claimed |
| US-20020052422-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2002-05-02 | — | — | US | claimed |
| EP-0696208-B1 | ORAL DRUG DELIVERY COMPOSITIONS | EMISPHERE TECH INC (US) | 2001-08-22 | — | — | EP | claimed |
| EP-1077070-A2 | Oral drug delivery compositions | Emisphere Technologies, Inc. (US) | 2001-02-21 | — | — | EP | claimed |
| US-5792451-A | AMINO ACID DERIVATIVES AS CARRIERS FOR SENSITIVE AGENTS SUCH AS BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-08-11 | — | — | US | claimed |
| US-5766633-A | MODIFIED AMINO ACID CARRIER, BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-16 | — | — | US | claimed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | claimed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | claimed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| US-5766633-A | MODIFIED AMINO ACID CARRIER, BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012817-A1 | Oral drug delivery compositions and methods | PTMS, ADM2, DNPEP | MME 95/4885LTA4H 1785/4885MMP2 1368/4885 |
| US-20020052422-A1 | Oral drug delivery compositions and methods | ADM2, PTMS, DNPEP | MME 106/4885LTA4H 2303/4885MMP2 1266/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | MME 182/4885LTA4H 320/4885MMP2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.